Moxalactam treatment of anaerobic infections in cancer patients.

Abstract

Of 30 patients with predominantly anaerobic localized infections superimposed on chronic tissue damage related to trauma, ischemia, or tumor, 22 (73%) responded satisfactorily to moxalactam therapy. Moxalactam-resistant anaerobic pathogens emerged in two patients and were responsible for treatment failure. In six patients, two of whom also acquired resistant anaerobic pathogens, isolation of moxalactam-resistant aerobic pathogens increased during therapy.

• Authors: H Lagast, F Meunier-Carpentier, J Klastersky
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 22 Issue 4 Pg. 604-10 (Oct 1982) ISSN: 0066-4804 [Print] United States
• PMID: 6217784 (Publication Type: Journal Article)

Chemical References

• Cephalosporins
• Cephamycins
• Moxalactam

Topics

• Adult
• Aged
• Anaerobiosis
• Bacterial Infections (complications, drug therapy, microbiology)
• Cephalosporins (therapeutic use)
• Cephamycins (therapeutic use)
• Drug Resistance, Microbial
• Female
• Humans
• Male
• Middle Aged
• Moxalactam
• Neoplasms (complications)